研究口服氯胺酮对耐药性慢性疼痛患者的疼痛、情绪和生活质量的影响。

IF 2.5 Q2 CLINICAL NEUROLOGY Frontiers in pain research (Lausanne, Switzerland) Pub Date : 2023-11-23 eCollection Date: 2023-01-01 DOI:10.3389/fpain.2023.1268985
Sammy Al Mukhaizeem, Anurag Nasa, Dympna Waldron, Alex McDaid, Patrick J Gorman, Molly Featherstone, Megan Barry, Paul Murphy, Hugh Gallagher, Shrijit Nair, Michael O'Connor, Linda Kelly, Emma O'Hora, Roisin Dolan, Siaghal Mac Colgain, Jack McGrath, Stephane Blouin, Elena Roman, Laura Gaffney, Darren William Roddy, Kirk John Levins
{"title":"研究口服氯胺酮对耐药性慢性疼痛患者的疼痛、情绪和生活质量的影响。","authors":"Sammy Al Mukhaizeem, Anurag Nasa, Dympna Waldron, Alex McDaid, Patrick J Gorman, Molly Featherstone, Megan Barry, Paul Murphy, Hugh Gallagher, Shrijit Nair, Michael O'Connor, Linda Kelly, Emma O'Hora, Roisin Dolan, Siaghal Mac Colgain, Jack McGrath, Stephane Blouin, Elena Roman, Laura Gaffney, Darren William Roddy, Kirk John Levins","doi":"10.3389/fpain.2023.1268985","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Chronic pain is defined as pain lasting longer than 3 months. This often causes persistent emotional distress and functional disability that is refractory to conventional treatments. Emerging evidence suggests that oral Ketamine therapy may have a specific role in managing treatment-resistant chronic pain. This study aimed to assess the effectiveness of oral ketamine within a tertiary chronic pain management clinic.</p><p><strong>Methods: </strong>This study was a clinic-based retrospective descriptive study of 79 patients with a broad range of chronic pain diagnoses and treated with oral ketamine over a period up to 12 years. Changes in pain, mood and quality of life (QoL) were assessed using a numerical pain severity score, the Brief Pain Inventory (BPI), the Public Health Questionnaire (PHQ-9) and American Chronic Pain Association Quality of Life (QoL) scale.</p><p><strong>Results: </strong>73 patients were accessible for follow-up (mean daily dose and treatment duration were 193.84 mg and 22.6 months respectively). Pain scores decreased (<i>p</i> < 0.0001) on both numerical scores (41.6% decrease) and BPI scoring (mean decrease 2.61). Mood improved (<i>p</i> < 0.0001) across both PHQ-9 and BPI measurements. Patients also reported less difficulty with daily activities and improved QoL. The most common adverse reaction was drowsiness (21.9%), with 30.1% reporting no adverse reactions from Ketamine.</p><p><strong>Discussion: </strong>This work adds to the growing body of evidence that under the supervision of a pain specialist, oral ketamine therapy may be a safe, tolerable and effective treatment for chronic pain conditions which have not responded to other management options. Further research is required to produce a more accurate understanding of its chronic use.</p><p><strong>Key message: </strong>This real-world study shows that patients being treated with oral ketamine for chronic pain report decreased severity of pain, improved mood and increased quality of life across all conditions.</p>","PeriodicalId":73097,"journal":{"name":"Frontiers in pain research (Lausanne, Switzerland)","volume":"4 ","pages":"1268985"},"PeriodicalIF":2.5000,"publicationDate":"2023-11-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10702242/pdf/","citationCount":"0","resultStr":"{\"title\":\"Investigating the effectiveness of oral ketamine on pain, mood and quality of life in treatment resistant chronic pain.\",\"authors\":\"Sammy Al Mukhaizeem, Anurag Nasa, Dympna Waldron, Alex McDaid, Patrick J Gorman, Molly Featherstone, Megan Barry, Paul Murphy, Hugh Gallagher, Shrijit Nair, Michael O'Connor, Linda Kelly, Emma O'Hora, Roisin Dolan, Siaghal Mac Colgain, Jack McGrath, Stephane Blouin, Elena Roman, Laura Gaffney, Darren William Roddy, Kirk John Levins\",\"doi\":\"10.3389/fpain.2023.1268985\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong>Chronic pain is defined as pain lasting longer than 3 months. This often causes persistent emotional distress and functional disability that is refractory to conventional treatments. Emerging evidence suggests that oral Ketamine therapy may have a specific role in managing treatment-resistant chronic pain. This study aimed to assess the effectiveness of oral ketamine within a tertiary chronic pain management clinic.</p><p><strong>Methods: </strong>This study was a clinic-based retrospective descriptive study of 79 patients with a broad range of chronic pain diagnoses and treated with oral ketamine over a period up to 12 years. Changes in pain, mood and quality of life (QoL) were assessed using a numerical pain severity score, the Brief Pain Inventory (BPI), the Public Health Questionnaire (PHQ-9) and American Chronic Pain Association Quality of Life (QoL) scale.</p><p><strong>Results: </strong>73 patients were accessible for follow-up (mean daily dose and treatment duration were 193.84 mg and 22.6 months respectively). Pain scores decreased (<i>p</i> < 0.0001) on both numerical scores (41.6% decrease) and BPI scoring (mean decrease 2.61). Mood improved (<i>p</i> < 0.0001) across both PHQ-9 and BPI measurements. Patients also reported less difficulty with daily activities and improved QoL. The most common adverse reaction was drowsiness (21.9%), with 30.1% reporting no adverse reactions from Ketamine.</p><p><strong>Discussion: </strong>This work adds to the growing body of evidence that under the supervision of a pain specialist, oral ketamine therapy may be a safe, tolerable and effective treatment for chronic pain conditions which have not responded to other management options. Further research is required to produce a more accurate understanding of its chronic use.</p><p><strong>Key message: </strong>This real-world study shows that patients being treated with oral ketamine for chronic pain report decreased severity of pain, improved mood and increased quality of life across all conditions.</p>\",\"PeriodicalId\":73097,\"journal\":{\"name\":\"Frontiers in pain research (Lausanne, Switzerland)\",\"volume\":\"4 \",\"pages\":\"1268985\"},\"PeriodicalIF\":2.5000,\"publicationDate\":\"2023-11-23\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10702242/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Frontiers in pain research (Lausanne, Switzerland)\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.3389/fpain.2023.1268985\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2023/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q2\",\"JCRName\":\"CLINICAL NEUROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in pain research (Lausanne, Switzerland)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3389/fpain.2023.1268985","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0

摘要

导言慢性疼痛的定义是持续 3 个月以上的疼痛。慢性疼痛通常会造成持续的精神痛苦和功能障碍,传统治疗方法难以奏效。新出现的证据表明,口服氯胺酮疗法可在治疗耐药性慢性疼痛方面发挥特殊作用。本研究旨在评估在一家三级慢性疼痛管理诊所中口服氯胺酮的有效性:本研究是一项以诊所为基础的回顾性描述性研究,研究对象是 79 名被诊断为多种慢性疼痛的患者,他们在长达 12 年的时间里接受了口服氯胺酮治疗。研究采用疼痛严重程度数字评分、简明疼痛量表(BPI)、公众健康问卷(PHQ-9)和美国慢性疼痛协会生活质量(QoL)量表评估疼痛、情绪和生活质量(QoL)的变化:73 名患者接受了随访(平均每日剂量和治疗时间分别为 193.84 毫克和 22.6 个月)。疼痛评分有所下降(p p 讨论):越来越多的证据表明,在疼痛专科医生的指导下,口服氯胺酮疗法可能是一种安全、可耐受且有效的慢性疼痛治疗方法。要想更准确地了解氯胺酮的长期使用情况,还需要进一步的研究:这项真实世界的研究表明,接受氯胺酮口服治疗的慢性疼痛患者报告称,在所有病症中,疼痛的严重程度均有所减轻,情绪有所改善,生活质量有所提高。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Investigating the effectiveness of oral ketamine on pain, mood and quality of life in treatment resistant chronic pain.

Introduction: Chronic pain is defined as pain lasting longer than 3 months. This often causes persistent emotional distress and functional disability that is refractory to conventional treatments. Emerging evidence suggests that oral Ketamine therapy may have a specific role in managing treatment-resistant chronic pain. This study aimed to assess the effectiveness of oral ketamine within a tertiary chronic pain management clinic.

Methods: This study was a clinic-based retrospective descriptive study of 79 patients with a broad range of chronic pain diagnoses and treated with oral ketamine over a period up to 12 years. Changes in pain, mood and quality of life (QoL) were assessed using a numerical pain severity score, the Brief Pain Inventory (BPI), the Public Health Questionnaire (PHQ-9) and American Chronic Pain Association Quality of Life (QoL) scale.

Results: 73 patients were accessible for follow-up (mean daily dose and treatment duration were 193.84 mg and 22.6 months respectively). Pain scores decreased (p < 0.0001) on both numerical scores (41.6% decrease) and BPI scoring (mean decrease 2.61). Mood improved (p < 0.0001) across both PHQ-9 and BPI measurements. Patients also reported less difficulty with daily activities and improved QoL. The most common adverse reaction was drowsiness (21.9%), with 30.1% reporting no adverse reactions from Ketamine.

Discussion: This work adds to the growing body of evidence that under the supervision of a pain specialist, oral ketamine therapy may be a safe, tolerable and effective treatment for chronic pain conditions which have not responded to other management options. Further research is required to produce a more accurate understanding of its chronic use.

Key message: This real-world study shows that patients being treated with oral ketamine for chronic pain report decreased severity of pain, improved mood and increased quality of life across all conditions.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
2.10
自引率
0.00%
发文量
0
审稿时长
13 weeks
期刊最新文献
Towards painless and productive research relationships: reflections on study design by a researcher with chronic pain for participants with chronic pain. Anatomical and physiological contributions of nasal turbinate vessels and lymphatics to the pathogenesis of nasal congestion in recurrent headaches: a pilot study. Editorial: Advancements in equine pain management. Healing synchrony? potential benefits of interpersonal synchrony for chronic pain management. Pain science education concepts for pelvic pain: an e-Delphi of expert clinicians.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1